Effects of dietary vitamin E supplementation on pulmonary morphology and collagen deposition in amiodarone- and vehicle-treated hamsters

Toxicology

Volumn 133, Issue 2-3, 1999, Pages 75-84

  Card, Jeffrey W ^a   Leeder, Randall G ^b   Racz, William J ^a   Brien, James F ^a   Bray, Tammy M ^c   Massey, Thomas E ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b Leo Laboratories Canada Ltd   (Canada)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Amiodarone; Dietary supplementation; Fibrosis; Lung; Pulmonary toxicity; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; HYDROXYPROLINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HAMSTER; HISTOCHEMISTRY; HISTOLOGY; INTRATRACHEAL DRUG ADMINISTRATION; LUNG INJURY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; COLLAGEN; CRICETINAE; DIETARY SUPPLEMENTS; HYDROXYPROLINE; LUNG; MALE; MESOCRICETUS; ORGAN SIZE; PULMONARY FIBROSIS; VEHICLES; VITAMIN E;

EID: 0033011583     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(99)00009-8     Document Type: Article

References (49)

1. Adams G.D., Kehoe R., Lesch M., Glassroth J. Amiodarone-induced pneumonitis: assessment of risk factors and possible risk reduction. Chest. 93:1988;254-263.
2. Bendich A., Machlin L.J. Safety of oral intake of vitamin E. Am. J. Clin. Nutr. 48:1988;612-619.
3. Blake T.L., Reasor M.J. Pulmonary responses to amiodarone in hamsters: Comparison of intratracheal and oral administrations. Toxicol. Appl. Pharmacol. 131:1995;325-331.
4. Bolt M.W., Racz W.J., Brien J.F., Bray T.M., Massey T.E. Effects of vitamin E on amiodarone-induced cytotoxicity in isolated hamster lung cells. Toxicologist. 48:1999;128.
5. Burton G.W., Joyce A., Ingold K.U. Is vitamin E the only lipid-soluble, chain-breaking antioxidant in human blood plasma and erythrocyte membranes? Arch. Biochem. Biophys. 221:1983;281-290.
6. Cantor J.O., Osman M., Cerreta J.M., Suarez R., Mandl I., Turino G.M. Amiodarone-induced pulmonary fibrosis in hamsters. Exp. Lung Res. 6:1984;1-10.
7. Chow C.K. Vitamin E and oxidative stress. Free Rad. Biol. Med. 11:1991;215-232.
8. Daniels J.M., Brien J.F., Massey T.E. Pulmonary fibrosis induced in the hamster by amiodarone and desethylamiodarone. Toxicol. Appl. Pharmacol. 100:1989;350-359.
9. Diplock A.T. The modulating influence of vitamin E in biological membrane and unsaturated phospholipid metabolism. Acta Vitaminol. Enzymol. 4:1982;303-309.
10. Franklin T.J. Current approaches to the therapy of fibrotic diseases. Biochem. Pharmacol. 49:1995;267-273.
11. Heger J.J., Prystowsky E.N., Zipes D.P. Relationships between amiodarone dosage, drug concentrations and adverse side effects. Am. Heart J. 106:1983;931-935.
12. Honegger U.E., Scuntaro I., Wiesmann U.N. Vitamin E reduces accumulation of amiodarone and desethylamiodarone and inhibits phospholipidosis in cultured human cells. Biochem. Pharmacol. 49:1995;1741-1745.
13. Hostetler K.Y., Giordano J.R., Jellison E.J. In vitro inhibition of lysosomal phospholipase A1 of rat lung by amiodarone and desethylamiodarone. Biochim. Biophys. Acta. 959:1988;316-321.
14. 1(l) gene expression in cultured human fibroblasts. Modulation of constitutive collagen gene expression by lipid peroxidation. J. Clin. Invest. 87:1991;2230-2235.
15. Kachel D.L., Moyer T.P., Martin W.J. Amiodarone-induced injury of human pulmonary artery endothelial cells: Protection by α-tocopherol. J. Pharmacol. Exp. Ther. 254:1990;1107-1112.
16. Kannan R., Sarma J.S.M., Guha M., Swaminathan N., Venkataraman K. Role of vitamin E in amiodarone-induced phospholipidosis in rats. FASEB J. 4:1990;1127A.
17. Kehrer J.P., Witschi H. The effect of indomethacin, prednisolone and cis-4-hydroxyproline on pulmonary fibrosis produced by butylated hydroxytoluene and oxygen. Toxicology. 20:1981;281-288.
18. Kehrer J.P., Klein-Szanto A.J.P., Sorensen E.M.B., Pearlman R., Rosner M.H. Enhanced acute lung damage following corticosteroid treatment. Am. Rev. Respir. Dis. 130:1984;256-261.
19. Kennedy J.I. Clinical aspects of amiodarone pulmonary toxicity. Clin. Chest Med. 11:1990;119-129.
20. Kennedy T.P., Gordon G.B., Paky A., McShane A., Adkinson N.F., Peters S.P., Friday K., Jackman W., Sciuto A.M., Gurtner G.H. Amiodarone causes acute oxidant lung injury in ventilated and perfused rabbit lungs. J. Cardiovasc. Pharmacol. 12:1988;23-36.
21. Kudenchuk P., Pierson D., Greene H., Graham E., Sears G., Trobaugh G. Prospective evaluation of amiodarone pulmonary toxicity. Chest. 86:1984;541-548.
22. Leeder R.G., Brien J.F., Massey T.E. Investigation of the role of oxidative stress in amiodarone-induced pulmonary toxicity in the hamster. Can. J. Physiol. Pharmacol. 72:1994;613-621.
23. Leeder R.G., Rafeiro E., Brien J.F., Mandin C.C., Massey T.E. Evaluation of reactive oxygen species involvement in amiodarone pulmonary toxicity in vivo and in vitro. J. Biochem. Toxicol. 11:1996;147-159.
24. Li A.S.W., Chignell C.F. Spectroscopic studies of cutaneous photosensitizing agents-IX. A spin trapping study of the photolysis of amiodarone and desethylamiodarone. Photochem. Photobiol. 45:1987;191-197.
25. Lindenschmidt R.C., Witschi H.P. Propranolol-induced elevation of pulmonary collagen. J. Pharmacol. Exp. Ther. 232:1985;346-350.
26. Lucy J.A. Functional and structural aspects of biological membranes: a suggested structural role of vitamin E in the control of membrane permeability and stability. Ann. N.Y. Acad. Sci. 203:1972;4-11.
27. Magro S.A., Lawrence E.C., Wheeler S.H., Krafchek J., Lin H.T., Wyndham C.R. Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests. J. Am. Coll. Cardiol. 12:1988;781-788.
28. Martin W.J., Kachel D.L., Vilen T., Natarajan V. Mechanism of phospholipidosis in amiodarone pulmonary toxicity. J. Pharmacol. Exp. Ther. 251:1989;272-278.
29. Mason J.W. Amiodarone. New Engl. J. Med. 316:1987;455-466.
30. Massey T.E., Leeder R.G., Rafeiro E., Brien J.F. The 1994 Veylien Henderson Award of the Society of Toxicology of Canada. Mechanisms in the pathogenesis of amiodarone-induced pulmonary toxicity. Can. J. Physiol. Pharmacol. 73:1995;1675-1685.
31. Pietrangelo A., Gualdi R., Casalgrandi G., Montosi G., Ventura E. Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents. J. Clin. Invest. 95:1995;1824-1831.
32. Rafeiro E., Leeder R.G., Brien J.F., Kabalka G.W., Chatla N., Massey T.E. Comparison of the in vivo pulmonary toxicity of amiodarone and des-oxo-amiodarone in the hamster. Toxicol. Appl. Pharmacol. 127:1994;275-281.
33. Reasor M.J., Kacew S. An evaluation of possible mechanisms underlying amiodarone-induced pulmonary toxicity. Proc. Soc. Exp. Biol. Med. 212:1996;297-304.
34. Redlich C.A., Grauer J.N., Van Bennekum A.M., Clever S.L., Ponn R.B., Blaner W.S. Characterization of carotenoid, vitamin A and α-tocopherol levels in human lung tissue and pulmonary macrophages. Am. J. Respir. Crit. Care Med. 154:1996;1436-1443.
35. Ruch R.J., Bandyopadhyay S., Somani P., Klaunig J.E. Evaluation of amiodarone free radical toxicity in rat hepatocytes. Toxicol. Lett. 56:1991;117-126.
36. Sato S., Nakamura H., Takada K., Takahashi K. Dietary vitamin E supplement does not inhibit changes in lung pressure-volume characteristics produced by bleomycin in hamsters. Eur. Respir. J. 1:1988;523-526.
37. Scuntaro I., Kientsch U., Wiesmann U.N., Honegger U.K. Inhibition by vitamin E of drug accumulation and of phospholipidosis induced by desipramine and other cationic amphiphilic drugs in human cultured cells. Br. J. Pharmacol. 119:1996;829-834.
38. Singh B.N. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am. J. Cardiol. 78:1996;41-53.
39. Sokal R.R., Rohlf F.J. Assumptions in analysis of variance. Kennedy D., Park R.B. Introduction to biostatistics. 1973;208-224 W.H. Freeman, San Francisco.
40. Statham C.N., Minchin R.F., Sasame H.A., Kim S.H., Boyd M.R. Effects of vitamin E on the distribution and metabolism of nitrofurantoin in rats. Drug Metab. Dispos. 13:1985;532-534.
41. Suntres Z.E., Shek P.N. Liposomal alpha-tocopherol alleviates the progression of paraquat-induced lung damage. J. Drug Targ. 2:1995;493-500.
42. Suntres Z.E., Shek P.N. Protective effect of liposomal alpha-tocopherol against bleomycin-induced lung injury. Biomed. Environ. Sci. 10:1997;47-59.
43. Taylor S.L., Lamden M.P., Tappel A.L. Sensitive fluorometric method for tissue tocopherol analysis. Lipids. 11:1976;530-538.
44. Tran K., Chan A.C. Effect of vitamin E enrichment on arachadonic acid release and cellular phospholipids in cultured human endothelial cells. Biochim. Biophys. Acta. 963:1988;468-475.
45. Urano S., Yano K., Matsuo M. Membrane-stabilizing effects of vitamin E: effect of α-tocopherol and its model compounds on fluidity of lecithin liposomes. Biochem. Biophys. Res. Commun. 150:1988;469-475.
46. van Acker S.A.B.E., Koymans L.M.H., Bast A. Molecular pharmacology of vitamin E: structural aspects of antioxidant activity. Free Rad. Biol. Med. 15:1993;311-328.
47. Vereckei A., Blazovics A., Gyorgy I., Feher E., Toth M., Szenasi G., Zsinka A., Foldiak G., Feher J. The role of free radicals in the pathogenesis of amiodarone toxicity. J. Cardiovasc. Electrophysiol. 4:1993;161-177.
48. Vrobel T.R., Miller P.E., Mostow N.D., Rakita L. A general overview of amiodarone toxicity: its prevention, detection and management. Prog. Cardiovasc. Dis. 31:1989;393-426.
49. Wang Q., Hollinger M.A., Giri S.N. Attenuation of amiodarone-induced lung fibrosis and phospholipidosis in hamsters by taurine and/or niacin treatment. J. Pharmacol. Exp. Ther. 262:1992;127-132.